In contrast, oseltamivir, zanamivir (drugs used for preventing influenza virus infection), and baricitinib (JAK1/2 inhibitor, which was recommended in ref. 21 to treat COVID-19) showed no inhibitory activities against SARS-CoV-2 at the concentration of 3 μM or 3.2 μM. This evidence concerns the gene JAK1 and COVID-19.